IGMS: igmbio.com Kompaniya qiymatining sof foydaga nisbati
Tizimli immun yetishmovchiliklar terapiyasi uchun texnologiyalarni qayta yo'naltirish istiqbollari onkologiya loyihalari yakunlangach aniq bo'ladi va tadqiqotlar uchun kapital rezervi allaqachon narxga kiritilgan. IGM Biosciences, Inc. (IGMS) kuchli nishon bog'lanishi tufayli analoglarni chetlab o'tuvchi noyob IgM tuzilmalarini yaratadi. -0.80 koeffitsiyenti bilan taqdim etilgan ushbu narxlar grafigi saratonga qarshi agentlarning tijorat chiqarilishiga yo'naltirilgan biznes tahlilini to'ldiradi.
%20P%2FE%20multiplikatori&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_IGMS_-_IGM-Biosciences-Inc._-_PE-Multiple "IGMS: IGM Bio Biznesning o‘zini qoplash muddati 04.07.2022 - 24.08.2025 | 👁️GURU.Markets👁️")
IGM Bio (IGMS) kompaniyasining tahliliy kesimlari
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning xususiy kapitalga nisbati IGM Biosciences, Inc.|IGMS - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati igmbio.com|IGMS - Kompaniya qarzlari|Qarzning balans qiymatiga nisbati IGM Biosciences Inc.|IGMS - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz IGM Biosciences|Oraliq qoplama koeffitsiyenti igmbio.com
- foyda va bozor multiplikatorlari tafsilotlari:
IGMS - Sof foyda|Prognoz qilingan sof foyda IGM Biosciences, Inc.|IGMS - Narxning foydaga nisbati|Prognoz qilingan narxning foydaga nisbati IGM Biosciences|IGMS - Narx-foyda va o‘sish multiplikatori|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati IGM Biosciences Inc.|IGMS - EBITDA operatsion foydasi|So'nggi o'n ikki oy davomida bir aksiya uchun foyda IGM Biosciences|IGMS - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik o'zgarishi igmbio.com|IGMS - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yilda bir aksiya uchun sof foydaning kutilayotgan o'sishi IGM Biosciences, Inc.
- realizatsiya hajmi va tushum ko'rsatkichlari:
Kompaniyaning har tomonlama tahlili:IGM Biosciences IGMS
Saraton bilan kurashish uchun innovatsion IgM antitanachalarini ishlab chiqish IGM Biosciences, Inc. (IGMS) uchun kapital intensivligi va qoplash muddatini belgilaydi. Foyda ko'rsatkichi (P/E) joriy tadqiqot va ishlanmalar (R&D) xarajatlarini kelajakdagi pul oqimiga bog'laydi. Ushbu koeffitsient investorlarning aktivlar ustidan nazorat uchun to'lashga tayyor bo'lgan premiumini o'lchaydi. Ushbu metrikadagi keskin tebranishlar bozor kutganlarining qayta ko'rib chiqilishi signalini beradi. IGM Biosciences, Inc. (IGMS) ning P/E dinamikasini tahlil qilish orqali investorlar pozitsiyaga kirishda haddan tashqari ko'p to'lashdan qochishlari mumkin.
Muhim raqobatchilar
P/E multiplikatori Argenx|Narx-foyda koeffitsiyenti BNTX (BioNTech Group)|ABVX (abivax.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ADMA (admabiologics.com)|Biznesning o‘zini qoplash muddati protagonist-inc.com (PTGX)|IMVT - Narxning foydaga nisbati|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Narx-foyda koeffitsiyenti|Grifols Biemat (GRFS) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Adaptive Biotechnologies|Narx-foyda koeffitsiyenti CLDX|P/E multiplikatori auriniapharma.com|Narxning foydaga nisbati BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Narx-foyda multiplikatori|P/E multiplikatori DNTH (dianthustx.com)|Pharvaris Pharma (PHVS) - Kapitalizatsiyaning foydaga nisbati|AbCellera Biologics - P/E multiplikatori|tourmalinebio.com - Bozor narxining sof foydaga nisbati|Precigen (PGEN) - Narxning foydaga nisbati|Pharming Group - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Nektar Therapeutics Inc|UPB (Upstream Pharma) - Bozor narxining sof foydaga nisbati|P/E multiplikatori ZBIO|P/E multiplikatori immunome.com (IMNM)|P/E multiplikatori GOSS (gossamerbio.com)|Biznesning o‘zini qoplash muddati KalVista Pharma (KALV)|SEPN - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning sof foydaga nisbati RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - P/E multiplikatori|ATXS (Astria Therapeutics, Inc.) - Bozor narxining sof foydaga nisbati|Narxning foydaga nisbati engene.com (ENGN)|RAPT (RAPT Therapeutics, Inc.) - Kompaniya qiymatining sof foydaga nisbati|Aerovate Therapeutics - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati ACRS|Kyverna Therapeutics, Inc - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati TLSA|CABA: P/E multiplikatori|Narx-foyda koeffitsiyenti Ventyx Bio|Narxning foydaga nisbati Theratechnologies, Inc.|Kapitalizatsiyaning foydaga nisbati Avalo Therapeutics AVTX|P/E multiplikatori ELDN|AGEN (Agenus, Inc.) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Climb Bio, Inc. CLYM|Zura Bio Limited (ZURA) - Kapitalizatsiyaning foydaga nisbati|ATYR: Narx-foyda koeffitsiyenti|adagene.com (ADAG) - Narx-foyda koeffitsiyenti|Ikena Oncology (IMA) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Shattuck Labs, Inc.|Narxning foydaga nisbati equilliumbio.com|Narx-foyda koeffitsiyenti connectbiopharm.com (CNTB)|P/E multiplikatori IMUX|Biznesning o‘zini qoplash muddati Atara Bio|Narxning foydaga nisbati InflaRx N.V. IFRX|X4 Pharmaceuticals - Narxning foydaga nisbati|ACET: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati CELU (celularity.com)|INMB: P/E multiplikatori|BRNS: Bozor narxining sof foydaga nisbati|KZR (Kezar Life Sciences, Inc.) - P/E multiplikatori|SAB Biotherapeutics Inc. (SABS) - Biznesning o‘zini qoplash muddati|P/E multiplikatori AKTX|Narxning foydaga nisbati ENLV (Enlivex Therapeutics Ltd)|Narxning foydaga nisbati Q32 Bio Inc. QTTB|GOVX - Narx-foyda koeffitsiyenti|EDSA - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati iBio|CARM: P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati XTLB (XTL Biopharmaceuticals, Ltd.)|Narxning foydaga nisbati boltbio.com|P/E multiplikatori HCW Biologics|P/E multiplikatori APVO|AIM - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori ADTX (Aditxt Inc.)|Biznesning o‘zini qoplash muddati GRI Bio, Inc. (GRI)|XRTX - Narxning foydaga nisbati|reshapelifesciences.com (HIND) - Narx-foyda koeffitsiyenti|REVB: P/E multiplikatori|Indaptus Therapeutics, Inc. - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Scinai|Kapitalizatsiyaning foydaga nisbati CalciMedica, Inc. CALI|Narxning foydaga nisbati Affimed NV (AFMD)|P/E multiplikatori Allakos Inc (ALLK)|Narxning foydaga nisbati hookipapharma.com HOOK|iTeos Therapeutics, Inc. (ITOS) - Kapitalizatsiyaning foydaga nisbati|OCEA: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E multiplikatori
